King Pharmaceuticals Inc Stock Current Ratio
| KG Stock | 26.95 0.23 0.85% |
Fundamental analysis of KING PHARMACEUTICALS allows traders to better anticipate movements in KING PHARMACEUTICALS's stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 6.08 | 3.43 |
KING | Current Ratio | Build AI portfolio with KING Stock |
KING PHARMACEUTICALS INC Company Current Ratio Analysis
KING PHARMACEUTICALS's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current KING PHARMACEUTICALS Current Ratio | 2.27 X |
Most of KING PHARMACEUTICALS's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, KING PHARMACEUTICALS INC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
KING Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for KING PHARMACEUTICALS is extremely important. It helps to project a fair market value of KING Stock properly, considering its historical fundamentals such as Current Ratio. Since KING PHARMACEUTICALS's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of KING PHARMACEUTICALS's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of KING PHARMACEUTICALS's interrelated accounts and indicators.
Click cells to compare fundamentals
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, KING PHARMACEUTICALS INC has a Current Ratio of 2.27 times. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
KING Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses KING PHARMACEUTICALS's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of KING PHARMACEUTICALS could also be used in its relative valuation, which is a method of valuing KING PHARMACEUTICALS by comparing valuation metrics of similar companies.KING PHARMACEUTICALS is currently under evaluation in current ratio category among its peers.
KING Fundamentals
| Current Valuation | 265.62 M | ||||
| Shares Outstanding | 9.94 M | ||||
| Shares Owned By Institutions | 100.00 % | ||||
| Number Of Shares Shorted | 65.4 K | ||||
| Price To Earning | 32.29 X | ||||
| Price To Book | 71.11 X | ||||
| Price To Sales | 51.37 X | ||||
| Revenue | 5.25 M | ||||
| EBITDA | 141.76 K | ||||
| Net Income | 324.27 K | ||||
| Cash And Equivalents | 545.31 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 244.12 K | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 2.27 X | ||||
| Cash Flow From Operations | (1.27 M) | ||||
| Short Ratio | 1.63 X | ||||
| Earnings Per Share | 0.03 X | ||||
| Market Capitalization | 267.87 M | ||||
| Total Asset | 4.7 M | ||||
| Retained Earnings | 947.82 M | ||||
| Working Capital | 3.74 M | ||||
| Current Asset | 1.13 B | ||||
| Current Liabilities | 496.9 M | ||||
| Net Asset | 4.7 M |
About KING PHARMACEUTICALS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze KING PHARMACEUTICALS INC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of KING PHARMACEUTICALS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of KING PHARMACEUTICALS INC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out KING PHARMACEUTICALS Piotroski F Score and KING PHARMACEUTICALS Altman Z Score analysis. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of KING PHARMACEUTICALS. If investors know KING will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about KING PHARMACEUTICALS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.03 |
The market value of KING PHARMACEUTICALS INC is measured differently than its book value, which is the value of KING that is recorded on the company's balance sheet. Investors also form their own opinion of KING PHARMACEUTICALS's value that differs from its market value or its book value, called intrinsic value, which is KING PHARMACEUTICALS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because KING PHARMACEUTICALS's market value can be influenced by many factors that don't directly affect KING PHARMACEUTICALS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between KING PHARMACEUTICALS's value and its price as these two are different measures arrived at by different means. Investors typically determine if KING PHARMACEUTICALS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, KING PHARMACEUTICALS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.